Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 33,088 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 2 Interventional Results available

A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

NCT02704364
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
NGM282, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Sacramento, California • San Clemente, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 22, 2026, 8:40 PM EDT
Not listed Phase 2 Interventional

The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

NCT03426085
View directory record Official record
Conditions
Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication
Interventions
Liraglutide 6 mg Solution for Injection, Placebo
Drug · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Lidocaine for Pessary Check Pain Reduction

NCT05493735
View directory record Official record
Conditions
Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions
Lidocaine Hcl 2% Jelly, Placebo Jelly
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 2 Interventional

A Controlled Study of Olanzapine in Children With Autism

NCT00057408
View directory record Official record
Conditions
Autistic Disorder
Interventions
olanzapine (Zyprexa), Placebo
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
3 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias

NCT02041325
View directory record Official record
Conditions
Plasma Cell Disorder
Interventions
Lenalidomide, Placebo
Drug
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia

NCT03482440
View directory record Official record
Conditions
Preeclampsia
Interventions
Salsalate Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Iowa City, Iowa • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

NCT03364491
View directory record Official record
Conditions
Obstetrical Complications, Hemorrhage, Labor and Delivery
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

NCT05592418
View directory record Official record
Conditions
Post COVID-19 Condition, Long COVID
Interventions
Rintatolimod, Placebo / Normal Saline
Drug · Other
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Canoga Park, California • Inglewood, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Not applicable Interventional

Do Arterial Catheters Reduce the Risk of Major Perioperative Complications

NCT02453815
View directory record Official record
Conditions
Postoperative Complications
Interventions
non-cardiac surgery, arterial catheter
Procedure · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 22, 2026, 8:40 PM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)

NCT07222189
View directory record Official record
Conditions
Colitis Ulcerative, Crohn's Disease
Interventions
balinatunfib, balinatunfib-matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
19 Years to 77 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Southlake, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 2 Interventional

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00429091
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, ADHD
Interventions
ABT-894, atomoxetine, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
22
States / cities
San Francisco, California • Wildomar, California • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 22, 2026, 8:40 PM EDT
Terminated Phase 3 Interventional Results available

Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza

NCT00610935
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
96
States / cities
Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

NCT03233308
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution 0.02%, Placebo Comparator
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 22, 2026, 8:40 PM EDT
Recruiting Phase 3 Interventional

Pridopidine Phase 3 Study in Huntington's Disease

NCT07609108
View directory record Official record
Conditions
Huntington Disease
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
23 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT03782376
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab approximately 6 mg/kg (IV), Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 22, 2026, 8:40 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

NCT05314517
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Namilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

NCT06368440
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6793, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 3 Interventional

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241540
View directory record Official record
Conditions
GERD
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
19
States / cities
Tucson, Arizona • Anaheim, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Not applicable Interventional

Melatonin for Sleep in MS

NCT04035889
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Melatonin, Placebo
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 22, 2026, 8:40 PM EDT
Recruiting Phase 1 Interventional

Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)

NCT06889168
View directory record Official record
Conditions
Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis
Interventions
Imatimib Mesylate, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New York, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

NCT03554291
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Right Heart Failure
Interventions
Famotidine 20 MG, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

NCT03371017
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Atezolizumab, Placebo, Gemcitabine, Capecitabine, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Paramus, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

NCT01620489
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Concord, California • La Jolla, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 22, 2026, 8:40 PM EDT
Completed Phase 1 Interventional

Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis

NCT03929068
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
carbidopa-levodopa, Placebo Oral Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 22, 2026, 8:40 PM EDT